Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase
- PMID: 3500183
- PMCID: PMC442392
- DOI: 10.1172/JCI113214
Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase
Abstract
Alpha 1-antitrypsin (alpha 1AT) deficiency resulting from homozygous inheritance of the Z-type alpha 1AT gene is associated with serum alpha 1AT levels of less than 50 mg/dl and the development of emphysema in the third to fourth decades. Despite the overwhelming evidence that the emphysema of PiZZ individuals develops because of a "deficiency" of alpha 1AT and hence an insufficient antineutrophil elastase defense of the lung, epidemiologic evidence has shown that levels of alpha 1AT of only 80 mg/dl protect the lung from an increased risk of emphysema. With this background, we hypothesized that homozygous inheritance of the Z-type may confer an added risk beyond a simple deficiency of alpha 1AT by virtue of an inability of the Z-type alpha 1AT molecule to inhibit neutrophil elastase as effectively as the common M1-type molecule. To evaluate this hypothesis, the functional status of alpha 1AT from PiZZ individuals (n = 10) was compared with that of alpha 1AT from PiM1M1 individuals (n = 7) for its ability to inhibit neutrophil elastase (percent inhibition) as well as its association rate constant for neutrophil elastase (K association). Plasma alpha 1AT concentration, measured by radial immunodiffusion, was 34 +/- 1 mg/dl in PiZZ patients vs. 237 +/- 14 mg/dl for PiM1M1 plasma, a sevenfold difference. When titrated against neutrophil elastase, the present inhibition of PiZZ plasma was significantly less than Pi M1M1 plasma (ZZ 78 +/- 1% vs. M1M1 95 +/- 1%, P less than 0.001) as was purified Z type alpha 1AT (ZZ, 63 +/- 2% vs. M1M1 86 +/- 2%, P less than 0.001). Sodium dodecyl sulfate (SDS) gel comparisons of the complexes formed with M1-type alpha 1AT and Z-type alpha 1AT with elastase demonstrated the Z alpha 1AT-elastase complexes were less stable than the M1 alpha 1AT-elastase complexes, thus releasing some of the enzyme to continue to function as a protease. Consistent with these observations, the K association of purified Z-type alpha 1AT for neutrophil elastase was lower than that of M1-type alpha 1AT (ZZ 4.5 +/- 0.3 X 10(6) M-1s-1 vs. M1M1 9.7 +/- 0.4 X 10(6) M-1s-1, P less than 0.001), suggesting that for the population of alpha 1AT molecules, the active Z-type molecules take more than twice as long as the active M1-type alpha 1AT to inhibit neutrophil elastase. Consequently, not only is there less alpha1AT in PiZZ individuals, but the population of Z-type alpha1AT molecules is less competent as an inhibitor of neutrophil elastase than M1-type alpha1AT molecules. This combination of defects suggests that PiZZ individuals have far less functional antielastase protection than suggested by the reduced concentrations of alpha1AT alone, further explaining their profound risk for development of emphysema.
Similar articles
-
Risk factors for emphysema. Cigarette smoking is associated with a reduction in the association rate constant of lung alpha 1-antitrypsin for neutrophil elastase.J Clin Invest. 1991 Mar;87(3):1060-5. doi: 10.1172/JCI115066. J Clin Invest. 1991. PMID: 1999486 Free PMC article.
-
Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase.Am Rev Respir Dis. 1988 Feb;137(2):364-70. doi: 10.1164/ajrccm/137.2.364. Am Rev Respir Dis. 1988. PMID: 3257660
-
Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency.J Clin Invest. 1989 Oct;84(4):1349-54. doi: 10.1172/JCI114305. J Clin Invest. 1989. PMID: 2794066 Free PMC article.
-
Genetics of alpha 1-antitrypsin deficiency in relation to neonatal liver disease.Mol Biol Med. 1990 Apr;7(2):161-72. Mol Biol Med. 1990. PMID: 2188061 Review.
-
Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency.Ann Allergy. 1994 Feb;72(2):105-20; quiz 120-2. Ann Allergy. 1994. PMID: 8109800 Review.
Cited by
-
Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency.Respir Med Case Rep. 2022 Sep 14;39:101740. doi: 10.1016/j.rmcr.2022.101740. eCollection 2022. Respir Med Case Rep. 2022. PMID: 36161236 Free PMC article.
-
Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1796-801. doi: 10.1073/pnas.97.4.1796. Proc Natl Acad Sci U S A. 2000. PMID: 10677536 Free PMC article.
-
A combined in silico and in vitro study on mouse Serpina1a antitrypsin-deficiency mutants.Sci Rep. 2019 May 16;9(1):7486. doi: 10.1038/s41598-019-44043-3. Sci Rep. 2019. PMID: 31097772 Free PMC article.
-
Safety and Reactogenicity of COVID-19 Vaccination in Severe Alpha-1 Antitrypsin Deficiency.Chronic Obstr Pulm Dis. 2024 Jan 25;11(1):3-12. doi: 10.15326/jcopdf.2023.0432. Chronic Obstr Pulm Dis. 2024. PMID: 37676644 Free PMC article.
-
Dual SORT LNPs for multi-organ base editing.Nat Biotechnol. 2025 Jun 2. doi: 10.1038/s41587-025-02675-z. Online ahead of print. Nat Biotechnol. 2025. PMID: 40457105
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous